2022 World Conference on Lung Cancer (ePosters)-EP16.02-002. Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study

EP16.02-002. Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study

Back to course

Pdf Summary

This document is a summary of a study titled "Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study" conducted by Anne C. Chiang and colleagues. The study aims to assess the association between longitudinal ctDNA levels and real-world response (rwR) to treatment in patients with metastatic non-small cell lung cancer (NSCLC) or extensive-stage small cell lung cancer (ES-SCLC) treated in community and academic settings.<br /><br />The study collected and linked data from multiple sources, including Foundation Medicine and Flatiron Health, to gather clinical data and perform genomic profiling on peripheral blood samples. A total of 944 patients were enrolled, and 354 ctDNA sample pairs were used to quantify changes in tumor fraction from baseline to follow-up.<br /><br />The results showed that patients with NSCLC who had a tumor response had greater decreases in tumor fraction compared to those with no tumor response. Increased ctDNA levels were associated with a higher risk of disease progression. The associations between ctDNA changes and rwR varied depending on the treatment type. There was a significant association between rwR and ctDNA change for cancer immunotherapy (CIT) alone or in combination, but not for chemotherapy.<br /><br />The study concluded that serial ctDNA assessment is feasible and may complement rwR in assessing treatment outcomes. However, the interpretation of ctDNA response may be influenced by the type of treatment received. The baseline tumor fraction varied among NSCLC and SCLC patients, and ctDNA changes were associated with rwR in patients receiving CIT alone or in combination, but not with chemotherapy.<br /><br />In summary, the study demonstrates the potential of ctDNA as a minimally invasive test for monitoring disease and investigating resistance in lung cancer patients. The findings suggest that ctDNA assessment could be used alongside rwR to evaluate treatment response, but further research is needed to understand the impact of different treatments on ctDNA changes.

Asset Subtitle

Anne Chiang

Meta Tag

Speaker Anne Chiang

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

Circulating Tumor DNA

ctDNA

Lung Cancer

Real-World Prospective Clinico-Genomic Study

Metastatic Non-Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

Community and Academic Settings

Genomic Profiling

Tumor Fraction

Treatment Response